Q-omics provides the consensus-scored CCDC126 profile across patient tissues and cancer cell-line models. CCDC126 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC126 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, CCDC126 RNA expression shows 20,254 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where CCDC126 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC126 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC126 survival associations across molecular data types. CCDC126 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC126 RNA expression–survival associations across cancer types. High CCDC126 expression shows unfavorable associations in LGG, CESC and KICH, but favorable associations in KIRC, PAAD and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC126 RNA expression.
This table summarizes CCDC126 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC126. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC126 shows lower tumor expression in THCA and KIRC and higher tumor expression in STAD, LIHC, BLCA and CHOL. The THCA box plot shows higher CCDC126 RNA expression in normal versus tumor tissue (log2 FC = −1.339, t-test p < 0.001).
This table shows molecular features associated with CCDC126 in patient tissues and cancer cell lines. In patient samples, CCDC126 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC126 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and CNS.
